Cydan, LLC, a Cambridge, Mass.-based orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, has just launched with $16m in financing.
The accelerator will focus on identifying promising assets across all therapeutic areas in rare diseases, with a focus on diseases and disorders with a characterized genetic etiology, with understood biology and proof-of-concept data in in vivo models from academia, industry and other sources.
Data generated during a de-risking process comprised of outsourced pharmacology, toxicology and other studies will enable it to form companies and strategic partnerships.
The accelerator was founded by
– Cristina Csimma, Pharm.D., Chief Executive Officer.
– Chris Adams, Ph.D., Chief Business Officer,
– James McArthur, Ph.D., Chief Scientific Officer, and
– and Deborah Geraghty, Ph.D., Vice President, Project and Portfolio Development.